“There is some evidence that there is altered brain activity related to reward-related behaviors, including appetite and ...

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between ...

The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in ...

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...